ClinicalTrials.gg
Active, not recruitingNCT04519749Updated Apr 8, 2024

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

A Phase 1/2 interventional study of 4D-310 in Fabry Disease, sponsored by 4D Molecular Therapeutics. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by 4D Molecular Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Fabry Disease with a site in United States — 13 open to participants now, 18 under way, 6 of them phase 3. Fabry Disease · United States.

Planned enrollment
35th of 58
18 · median 22
Started
2020
with 3 others
Phase 1/2
7 of 94
1 open now
Primary completion
2026-01
later than 2 of 17 live
Registered
76th of 94
by date

Among the 94 studies in Fabry Disease with a site in United States, this one is the 35th largest by planned enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2020, is one of 7 in phase 1/2, reaches primary completion later than 2 of the 17 other live ones, and was the 76th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

13 of the 94 studies in Fabry Disease with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Fabry Disease with a site in United States, or all of them as a file.
02

Study summary

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.

Read the detailed description

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.

03

Conditions studied

  • Fabry Disease

Keywords

  • Lysosomal Storage Diseases
  • Nervous System Brain Diseases
  • Metabolic
  • Inborn Brain Diseases
  • Metabolic Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Cerebral Small Vessel Diseases
  • Cerebrovascular Disorders
  • Vascular Diseases
  • Cardiovascular Diseases
  • Genetic Diseases
  • X-Linked
  • Inborn
  • Metabolic Diseases
  • Lipid Metabolism Disorders
  • Sphingolipidoses
  • Metabolism
  • Inborn Errors
  • Lipidoses
  • Lipid Metabolism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. Pathogenic GLA mutation consistent with Fabry Disease
  3. Confirmed diagnosis of classic or late-onset Fabry disease
  4. Individuals on ERT must be on a stable dose for at least 6 months (and a minimum of 12 months total exposure) prior to study enrollment
  5. Agree to use highly effective

Exclusion criteria

Exclusion Criteria:

  1. Presence of high titer neutralizing antibody to 4D-310 capsid, or presence of high antibody titer to AGA
  2. \<45 mL/min/1.73 m2
  3. Undergone kidney transplantation or currently on hemodialysis or peritoneal dialysis
  4. , active or chronic or C,
  5. Evidence of liver disease, severe pulmonary disease or diabetes with poor glycemic control
  6. History of stroke or within the last 12 months, or other significant thromboembolic disease history (e.g. pulmonary embolism)
  7. to systemic therapy or therapy
  8. Chronic steroid use, defined as ≥ 3 months of oral corticosteroid use within the last 12 months.
  9. Moderately severe to severe cardiovascular disease or uncontrolled hypertension
  10. of \<45% on echocardiogram (ECHO)
  11. Currently receiving drug, device or therapy or having ever received gene therapy
  12. History of infusion related response to ERT or any adverse reaction leading to ERT discontinuation
  13. History of cancer within 2 years (exceptions include non-melanoma skin cancer, localized prostate cancer treated with curative intent)
  14. Pregnant or breast-feeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A

    Single IV administration of 4D-310 Dose Level 1 - AAV NAb Titer Group A patients

    Biological: 4D-310

  • Experimental
    4D-310 Dose Level 1 - AAV NAb Titer Group B

    Single IV administration of 4D-310 Dose Level 1 - AAV NAb titer Group B patients

    Biological: 4D-310

  • Experimental
    4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B

    Single IV administration of 4D-310 at Dose Level 2 in AAV NAb titer Group A and/or B patients

    Biological: 4D-310

  • Experimental
    4D-310 Dose Expansion

    Dose expansion cohort of single IV administration of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients

    Biological: 4D-310

Interventions

  • Biological4D-310

    4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Safety and tolerability of 4D-310 following a single IV dose, as assessed by incidence and severity of adverse events, serious adverse events and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters

    Time frame: 1 year

Secondary outcomes

  1. Change from baseline in serum AGA activity

    Change from baseline in serum AGA activity

    Time frame: 1 year

  2. Change from baseline serum globotriaosylsphingosine (lysoGb3)

    Change from baseline serum globotriaosylsphingosine (lysoGb3)

    Time frame: 1 year

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jan 2026, 64 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 20, 2020
StartActual
Sep 1, 2020
Primary completionEst.
Jan 2026
CompletionEst.
Jun 2030
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04519749
Lead sponsor
4D Molecular Therapeutics
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Sep 1, 2020
Primary completion
Jan 2026 (estimated)
Completion
Jun 2030 (estimated)
Last update
Apr 8, 2024

Study contacts

Alan H Cohen, MD
study director · 4D Molecular Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion